secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001534120-26-000016
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Two Avalo Therapeutics directors to not stand for re-election at 2026 Annual Meeting
--------------------------------------------------------------------------------

- Dr. Jonathan Goldman and Mitchell Chan will not stand for re-election to the Board at the 2026 Annual Meeting.
- They will continue to serve as board members until the 2026 Annual Meeting.
- Decisions are not due to any disagreement with the Company regarding operations, policies, or practices.
- The Board expressed gratitude for their service and contributions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000016/0001534120-26-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412026000016/avtx-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001534120-26-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer